ARZERRA J Code: J9302

Drug & Product Overview

HCPCS Descriptor Injection, ofatumumab, 10 mg

HCPCS Added Date January 1, 2011

Manufacturer Novartis

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About ARZERRA

Arzerra is a medication aligned to the HCPCS J Code: J9302 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Novartis.

Manufacturers, reach out to us to add more information.

NDC Code Information

3 NDC packages are crosswalked to J9302. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	ARZERRA
	ARZERRA
	ARZERRA

Login to view 3 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ARZERRA Pricing & Reimbursement

J9302 Private Payer Reimbursement

$63.17 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

ARZERRA CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Arzerra (J9302) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ARZERRA Medically Unlikely Edits (MUE)

The most billing units of J9302 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

200 units / day

= 2,000 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

ARZERRA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Chronic lymphocytic leukemia

Drug Class

CD20-directed Antibody Interactions [MoA]CD20-directed Cytolytic Antibody [EPC]

Frequently Asked Questions

Is there an available Arzerra billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for ARZERRA.

Are there any available Arzerra patient assistance programs?

ARZERRA patient assistance information can be found through Novartis. Visit Here →

Where can I find Arzerra prescribing information?

ARZERRA prescribing information can be found at the link below: Visit Here →

Where can I find Arzerra side effect information?

Information regarding ARZERRA's side effects can be found at MedlinePlus Visit Here →

Does billing ARZERRA require JZ/JW wastage modifiers?

CMS has identified ARZERRA(J9302) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.